The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ANALYSIS-Buy yen in crisis? Not this year

Tue, 24th Jul 2018 15:08

* Yen weakest G10 currency this month despite globalturbulence

* Investors doubt BOJ can reduce stimulus aggressively

* Japanese purchases of foreign equities highest in nearly 3years

* Bond investors growing reluctant to hedge foreign holdings

* Japanese firms spend record sum on foreign acquisitions inH1

By Tom Finn and Hideyuki Sano

LONDON/TOKYO, July 24 (Reuters) - The trade is familiar toinvestors worldwide: in times of turmoil, rush for cover bybuying the Japanese yen.

This year a global trade row has erupted, Donald Trump haslamented the dollar's strength - ignoring a custom that U.S.presidents avoid openly interfering in financial markets - andthe Chinese yuan has tumbled.

And yet the yen has stayed resolutely weak, becoming theweakest of the G10 developed market currencies this month.

The yen's safe-haven status is not in doubt, underpinned byJapan's nearly two trillion yen ($18 billion) monthly tradesurplus. But without a massive world market shock to discourageJapanese investors from buying foreign assets, the yen is likelyto stay weak - above all because the Bank of Japan lags behindits central bank peers in ending monetary stimulus.

Investors doubt the BOJ can aggressively reduce the stimulusmeasures as inflation remains well below target and corporateprofits are recovering slowly.

The BOJ is debating policy changes to make its stimulus"more sustainable", sources told Reuters, but this pushed theyen up only briefly on Monday.

"The Bank of Japan is still pursuing easing which is stillprompting domestic investors to borrow yen and buy overseasassets," said Anton Eser, CIO at Legal and General InvestmentManagement which manages 983 billion pounds ($1.29 trillion) inassets.

While U.S. interest rates have risen seven times since 2016and the European Central Bank plans to wind down its bondpurchases by end-2018, the BOJ is still buying local securities,albeit at a slower pace.

Japanese investors are therefore likely to keep pouringmoney into foreign assets, despite global market wobbles.

Their net purchases of foreign equities reached 1.5 trillionyen in June, the highest in nearly three years. Even as thetrade row deepened, they bought 371 billion yen of overseasstocks during the first week of July.

HEDGE TRIMMING

However, Japanese funds are growing reluctant to hedgeexposure to billions of dollars' of U.S. assets.

"I suspect some investors are reducing currency hedge ontheir foreign bond investments," a senior trader at a majorJapanese bank in Tokyo told Reuters, requesting anonymity.

Japanese fund managers buying 10-year U.S. Treasuries on afully hedged basis now earn a slim 33 basis points in yield,compared with 50-80 bps last year. As the Federal Reserve keepsraising interest rates, even that yield advantage could vanish.

And a lack of demand for yen from investors in the currencyforwards market would feed into falling spot market demand.

"Currency hedging costs have risen rapidly. Japaneseinvestors have stopped hedging. That stops them buying the yen.The flow is for selling yen," said Adam Cole, chief currencystrategist at RBC in London.

Another source of yen selling is Japanese companies makingacquisitions overseas due to lacklustre economic growth and ashrinking population at home. Thomson Reuters data showsJapanese investors spent a record 13.0 trillion yen on foreignacquisitions in the first half of the year.

These included Takeda Pharmaceutical's $62 billionacquisition of London-listed drugmaker Shire Plc.

Initially the deal helped to push the British pound up morethan four percent against the yen in early-April, but in Maytraders started to buy dollars on news that Takeda's payment toShire shareholders would be in dollars.

TRADE WINDS

Trade conflict would seem yen-positive by raising globalmarket volatility. In fact, this is helping to push it down.

Japan is vulnerable to a trade war. Autos, for instance,comprise almost 30 percent of its exports to the United Statesand new U.S. tariffs could hurt Tokyo's vaunted trade surplus.

Also, as fund managers worldwide cut foreign investmentholdings, much of this cash is going to U.S. markets instead ofthe "safe havens". The dollar is likely to benefit from a tradewar due to the United States' lower reliance on exports.

"Rather than move into the Swiss franc or the Japanese yen,the widening interest rate differential in favour of the U.S.dollar is currently providing investors with a strongalternative," Rabobank currency strategist Jane Foley said.

Global investors now hold their biggest overweight positionin U.S. equities in 17 months, Bank of America Merrill Lynch'spoll showed last week. Other equity holdings have fallen andallocations to Japan slid for the third time in four months.

Correlation has been high this year between Japanese stocksand the yen, with both losing ground, BAML's FX strategist KamalSharma noted. That's unusual because yen weakness usually booststhe Nikkei average.

"If U.S. share markets crumbled, then we would be in adifferent situation," the Tokyo-based trader said. "But as longas Wall Street is in the risk-on mode, the dollar will besupported against the yen."($1 = 111.2400 yen)($1 = 0.7629 pounds)

(Additional reporting by Shinji Kitamura and Tommy Wilkes;Graphic by Ritvik Carvalho; Writing by Saikat Chatterjee;Editing by Sujata Rao and David Stamp)

More News
24 Aug 2018 11:54

LONDON MARKET MIDDAY: Stocks Up; Powell To Make Jackson Hole Debut

LONDON (Alliance News) - Stocks in London were marginally higher at midday on Friday ahead of a highly anticipated speech from the head of the US Federal Reserve.With US-China trade talks demoting a

Read more
24 Aug 2018 10:39

WINNERS & LOSERS SUMMARY: Shire Rises As US FDA Approves Takhzyro Drug

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 2.6%. The Irish pharmaceutical company said a

Read more
24 Aug 2018 08:38

LONDON MARKET OPEN: Stocks Mixed, Shire Rises After Drug Approval

LONDON (Alliance News) - Stock prices in London were mixed early Friday, as markets await US Federal Reserve Chair Jerome Powell's speech in Wyoming later in the day. In the large cap index rose

Read more
24 Aug 2018 08:06

FDA gives nod to Shire's TAKHZYRO treatment

(Sharecast News) - Shire announced on Friday that, following priority review, the US Food and Drug Administration (FDA) has approved the 'TAKHZYRO' (lanadelumab-flyo) injection for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older.

Read more
24 Aug 2018 07:41

LONDON MARKET PRE-OPEN: Slightly Lower Call Ahead Of Powell Speech

LONDON (Alliance News) - Stock prices in London are seen lower on Friday ahead of US Federal Reserve Chair Jerome Powell's speech later during the day, while in a quiet day for UK company news In

Read more
13 Aug 2018 10:31

WINNERS & LOSERS SUMMARY: Chemring Says Fatal Accident To Hurt Profit

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------BAE up 0.8%. a

Read more
13 Aug 2018 09:21

Shire Partner Shionogi Files New Drug Application For Intuniv In Japan

LONDON (Alliance News) - Irish drugmaker Shire PLC said on Monday its Japanese partner Shionogi & Co Ltd has submitted a new drug application for the manufacture and marketing of Intuniv in is

Read more
13 Aug 2018 07:51

Shire and Shionogi apply to expand ADHD treatment to adults

(Sharecast News) - Shire and Shionogi have applied to expand the use in Japan of co-developed drug Intuniv to treat adults for attention deficit hyperactivity disorder.

Read more
31 Jul 2018 12:51

TOP NEWS: Shire Income Up In 2nd-Quarter Ahead Of Takeover By Takeda

LONDON (Alliance News) - Irish biotechnology company Shire PLC on Tuesday posted a more than doubled pretax income in the second quarter, ahead of its upcoming takeover by Takeda Pharmaceutical Co

Read more
31 Jul 2018 12:12

Shire posts 4 pct rise in Q2 earnings ahead of sale to Takeda

LONDON, July 31 (Reuters) - Shire, the London-listed pharmaceutical group being bought by Japan's Takeda, reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to just

Read more
31 Jul 2018 12:08

Shire's quarterly sales rise on immunology demand

(Sharecast News) - Shire reported healthy sales growth in the second quarter as the biotech company pressed ahead with its acquisition by Takeda of Japan.

Read more
31 Jul 2018 08:05

UPDATE 1-Takeda posts weakest Q1 profit in three years

* Q1 operating profit Y98.9 bln vs Y195 bln a year earlier * Takeda booked gains from asset sales a year earlier (Adds details) TOKYO, July 31 (Reuters) - Japan's Takeda Co Ltd a

Read more
25 Jul 2018 07:00

RPT-ANALYSIS-Buy yen in crisis? Not this year

* Yen weakest G10 currency this month despite global turbulence * Investors doubt BOJ can reduce stimulus aggressively * Japanese purchases of foreign equities highest in nearly Bond

Read more
24 Jul 2018 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 25 July GlaxoSmithKlineHalf Year Results (at 1200 BST)Vodafone GroupTrading 26

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.